Select Page

Investor Information

At Sun, we remain committed to creating long term value for our shareholders. In line with this philosophy, we will continue to focus on performance and producing consistent returns.

Statutory Communications

Composite Scheme of Arrangement

Related Party Transactions for the half year ended September 30, 2023

Stock Exchange Letter Disclosure of Q2FY24 Earnings Call Audio Recording

Intimation of Board Meeting

Intimation of Schedule of Analyst/Institutional Investor Meeting

ESG Overview FY2022-23

Webcast Recording of 31st Annual General Meeting of the Company

Intimation of Schedule of Analyst/ Institutional Investor Meeting

Intimation of Schedule of Analyst/Institutional Investor Meeting

Intimation of Schedule of Analyst/Institutional Investor Meeting

Related Party Transactions for the half year ended March 31, 2023

Stock Exchange Letter Disclosure of Q1FY24 Earnings Call Audio Recording

Tax on Dividend for Final Dividend

Dividend Waiver Form

Stock Exchange Letter Intimation of Schedule of Analyst / Institutional Investor Meeting

Update relating to earnings call

Non-binding indication of interest to acquire shares of Taro Pharmaceutical Industries Ltd., Israel

Appointment of Director

Stock Exchange Letter Intimation of Schedule of Analyst / Institutional Investor Meeting

Stock Exchange Letter Disclosure of Q4FY23 Earnings Call Audio Recording

Update on US FDA Inspection at Mohali Facility

Update on IT Security Incident

Stock Exchange Letter Intimation of Schedule of Analyst / Institutional Investor Meeting

Stock Exchange Letter Intimation of Schedule of Analyst / Institutional Investor Meeting

Intimation of IT Security Incident

Interim Dividend Waiver Form for the financial year 2022-23

Stock Exchange Letter Intimation of Schedule of Analyst / Institutional Investor Meeting

Stock Exchange Letter Disclosure of Earnings Call Audio Recording

Outcome of postal ballot and disclosure of voting results- Appointment of Mr. Sanjay Asher as an Independent Director

Sustainability Report 2021-22

Notice of Postal Ballot for Appointment of Mr. Sanjay Asher & Postal Ballot Form

Related Party Transactions for half year ended 30.09.2022

Stock Exchange Letter Intimation of Schedule of Analyst / Institutional Investor Meeting

Stock Exchange Letter Disclosure of Earnings Call Audio Recording

Stock Exchange Letter Intimation of Schedule of Analyst / Institutional Investor Meeting

Webcast Recording of 30th AGM

Voting Results and Scrutinizer’s Report of 30th AGM

ESG Overview 2021-22

Stock Exchange Letter Intimation of Schedule of Analyst / Institutional Investor Meeting

Publication for 30th AGM and Evoting

Publication of 30th Annual General Meeting to be held by VC

Form for waiver-forgoing right to receive Final Dividend for financial year 2021-22

Intimation under Regulation 30 – Retirement of Chairman

Publication of unaudited financial results for Q1

Intimation of the 30th Annual General Meeting

Stock Exchange Letter Disclosure of Earnings Call Audio Recording

Self-declaration for Non-resident Shareholder

Outcome of Board Meeting – July 2022

Intimation of Board Meeting July 2022

Closure of Trading Window Q1 (2022-23)

Consolidated Related Party Transactions for half year ended 31.03.2022

Stock Exchange Letter Intimation of Schedule of Analyst / Institutional Investor Meeting

Intimation under Regulation 30 – 31 May 2022

Stock Exchange Letter Disclosure of Earnings Call Audio Recording

Outcome of Board Meeting – May 2022

Intimation under Regulation 30 – 30 May 2022 (Approval of Scheme of Amalgamation)

Intimation under Regulation 30 – 30 May 2022 (Appointment of Lead Independent Director/ Re-appointment of Directors)

Annual Secretarial Compliance Report

Stock Exchange Letter Intimation of Schedule of Analyst / Institutional Investor Meeting

Intimation of Board Meeting May 2022

Intimation under Regulation 30 – 10th May, 2022

Intimation under Regulation 30- 29th March, 2022

Intimation under Regulation 30 – March 21, 2022

Intimation under Regulation 30- 8th March, 2022

Intimation under Regulation 30 – February 22, 2022

Intimation under Regulation 30- 1st February, 2022
 
Intimation under Regulation 30- 25th March, 2022

Disclosure under Regulation 30 of SEBI Listing Regulations – Signing of Binding Memorandum of Understanding as to Material Terms of Settlement with the Direct Purchaser and End-Payor Plaintiffs in the In re Ranbaxy Generic Drug Application Antitrust Litigation in the U.S. District Court for the District of Massachusetts (USA)

Closure of Trading Window

Stock Exchange Letter Intimation of Schedule of Analyst / Institutional Investor Meeting

Stock Exchange Letter Intimation of Schedule of Analyst / Institutional Investor Meeting

Stock Exchange Letter Intimation of Schedule of Analyst / Institutional Investor Meeting

Interim Dividend Waiver Form_2021-22

Outcome of Board Meeting held on Jan 31, 2022

Intimation under Regulation 30- 27th January, 2022

SPIL Intimation of Board Meeting January 2022

Intimation under Regulation 30- 28th December, 2021

Intimation under Regulation 30- 15th December, 2021

Consolidated Related Party Transactions for half year ended 30.09.2021

Intimation under Regulation 30- 30th November, 2021

Stock Exchange Letter Intimation of Schedule of Analyst / Institutional Investor Meeting

Stock Exchange Letter Intimation of Schedule of Analyst / Institutional Investor Meeting

Intimation under Regulation 30- 11th November, 2021

Stock Exchange Letter Intimation of Schedule of Analyst / Institutional Investor Meeting

Signing of settlement agreements with the Direct Purchaser Plaintiffs in the In re Generic Pharmaceuticals Pricing Antitrust Litigation in the Eastern District of Pennsylvania (USA) by our 2 subsidiary companies.

Outcome of Board Meeting held on Nov 02, 2021

Closure of trading window

Stock Exchange Letter Intimation of Schedule of Analyst / Institutional Investor Meeting

Stock Exchange Letter Intimation of Schedule of Analyst / Institutional Investor Meeting

Webcast Recording of 29th Annual General Meeting of the Company

Intimation under Regulation 30- 28th September, 2021

Intimation to exchange Sanction of Scheme of Amalgamation and Merger of Sun Pharma Global FZE with SPIL

Sun Pharma forays into Nutrition Bar segment with the launch of Revital NXT

Stock Exchange Letter Intimation of Schedule of Analyst / Institutional Investor Meeting

Resignation of Mr. Vivek Channd Sehgal

Intimation under Regulation 30- 1st September, 2021

Voting Results of 29th AGM and Scrutiniser’s Report

Proceedings of 29th AGM and Intimation of Changes in Directors

Chairman Speech at the 29th Annual General Meeting held on 31 August 2021

Newspaper Advertisement for Notice of 28th Annual General Meeting and E-voting – Post-dispatch

Form for waiver-forgoing right to receive Final Dividend for financial year 2020-21

Newspaper Advertisement for Notice of 28th Annual General Meeting, E-voting and Book Closure – Pre-dispatch

SPIL Intimation of AGM and Book Closure

Outcome of Board Meeting held on July 30, 2021

Newspaper Advertisement for Notice for transfer of equity shares and unclaimed Dividend to IEPF

SPIL Intimation of Board Meeting July 2021

Annual Secretarial Compliance Report

Consolidated Related Party Transactions for half year ended 31.03.2021

Stock Exchange Letter Intimation of Schedule of Analyst / Institutional Investor Meeting

Intimation of Acquisition of trademarks and patent license for Dapagliflozin and its combinations from AstraZeneca AB

Stock Exchange Letter Intimation of Schedule of Analyst / Institutional Investor Meeting

Outcome of the Board Meeting – May 2021

Intimation for Appointment of Additional Independent Directors on the Board of the Company

SPIL Intimation of Board Meeting May 2021

Intimation under Regulation 30 of Listing Regulations

Clarification to Stock Exchanges on News Item

Intimation under Regulation 30 of Listing Regulations

Webcast Recording for Tribunal Called Meeting of Equity Shareholders of the Company held on March 16, 2021

Intimation under Regulation 30 of Listing Regulations

Intimation under Regulation 30 of Listing Regulations

Voting Results of the NCLT Convened Meeting of Equity Shareholders held on March 16, 2021 and Scrutinizer’s Reports

Proceedings of the NCLT Convened Meetings of Unsecured Creditors and Equity Shareholders held on March 16, 2021

Update on Intimation under Regulation 30 of Listing Regulations

Intimation under Regulation 30 of Listing Regulations

Newspaper Advertisement for NCLT Meetings of Equity Shareholders and Unsecured Creditors

Intimation Letter for Conclusion of settlement proceedings with SEBI

Notice of NCLT Convened Meeting of Unsecured Creditors

Notice of NCLT Convened Meeting of Equity Shareholders

Newspaper Advertisement for Intimation of Record Date for Payment of Interim Dividend

FORM NO 15G

Interim Dividend Waiver Form_2020-21

FORM NO 15H

Outcome of the Board Meeting – January 2021

FORM NO 10F

Intimation to Stock Exchange for considering Declaration of Interim Dividend

SPIL Intimation of Board Meeting January 2021

StockExchangeIntimationSUNAZ28052021

Webcast Recording of 28th Annual General Meeting of the Company for the year 2019-20

Outcome of Board Meeting – November 2020

SPIL Intimation of Board Meeting November 2020

Scheme of Amalgamation and Merger

Board Resolution approving Scheme of Amalgamation and Merger

Related Party Disclosure on consolidated basis for the half year ended September 30, 2020

Post Buy-Back Public Announcement – September 26, 2020

Intimation of Closure of Buy Back – September 25, 2020

Secretarial Audit Report of Material Subsidiaries_2019-20

Voting Results for the 28th Annual General Meeting and Scrutinizer’s Consolidated Report

Outcome of 28th Annual General Meeting

Chairman Speech at the 28th Annual General Meeting held on 27 August 2020

Newspaper Advertisement for Notice of 28th Annual General Meeting, E-voting and Book Closure

BUSINESS RESPONSIBILITY REPORT -FY2019-20

Self Declaration Format for Non-Resident Shareholders

Notice of the 28th Annual General Meeting

SPIL ANNUAL REPORT -FY2019-20

EMPLOYEES’ STOCK OPTION SCHEME-Disclosure under SEBI (Share Based Employee Benefits)Regulations2014 as on Mar 312020

Update on Intimation under Regulation 30 of Listing Regulations

Form for waiver-forgoing right to receive Final Dividend for financial year 2019-2020_Final

Intimation under Regulation 30 of Listing Regulations

Outcome of the Board Meeting – July 2020

Newspaper Advertisement for Notice for transfer of equity shares and unclaimed Dividend to IEPF

SPIL Intimation of Board Meeting July 2020

Related Party Disclosure on consolidated basis for the half year ended March 31, 2020

Outcome of Board Meeting – May 2020

SPIL Intimation of Board Meeting May 2020

Stock Exchange Letter Update on Halol facility

Additional details for OAI classification for Halol facility

Corrigendum to Public Announcement for Buy-Back of Equity Shares – March 24, 2020

Public Announcement for Buy-Back of Equity Shares – March 18, 2020

Outcome of the Board Meeting March 2020 – Approval of Buy-Back

SPIL Intimation of Board Meeting March 2020

Newspaper Advertisement for Intimation of Record Date for payment of Interim Dividend

Outcome of the Board Meeting – February 2020

Interim Dividend Waiver Form

Intimation to Stock Exchange for considering Declaration of Interim Dividend

SPIL Intimation of Board Meeting February 2020

Intimation to Stock Exchange for NCLT Order on Composite Scheme of Arrangement

Update on US FDA Halol Inspection

Stock Exchange Letter Antitrust Litigation in US

Outcome of Board Meeting – November 2019

SPIL Intimation of Board Meeting November 2019

Related Party Disclosure on consodilated basis for half year ended September 30, 2019

Chairman Speech at the 27th Annual General Meeting held on August 28, 2019

Outcome of Board Meeting – August 2019

Clarification/Confirmation on News Item

Newspaper Advertisement for Notice of 27th Annual General Meeting, E-voting and Book Closure

SPIL Intimation of Board Meeting August 2019

SPIL Intimation of AGM date and Book Closure

EMPLOYEES’ STOCK OPTION SCHEMES – Disclosure under SEBI (Share Based Employee Benefits) Regulations, 2014 as on March 31, 2019

Business Responsibility Report FY2018-19

Dividend Waiver Form 2018-19

Voting Results alongwith Scrutinizer’s Report of TCM held on June 04, 2019

Proceedings of the NCLT Convened Meeting of Shareholders and Unsecured Creditors

Stock Exchange clarification on news item

Scrutinizer Report SPIL NCLT Meeting 04 06 2019 Unsecured Creditors

Advertisement for Notice for transfer of equity shares and unclaimed dividend to IEPF

Notice of Tribunal Convened Meeting Unsecured Creditors June 04, 2019

Outcome of the Board Meeting – May 28, 2019

SPIL Intimation of BM May 2019

Stock Exchange Intimationm Of Advertisement

Sun Pharma – Attendance Slip for NCLT Convened Meeting for Equity Shareholders

Sun Pharma – Notice of NCLT Convened Meeting including Proxy Form and Attendance Slip for Equity Shareholders

Sun Pharma – Proxy Form for NCLT Convened Meeting for Equity Shareholders

Related Party Disclosure on consolidated basis for half year ended 31st March, 2019

Notice of Board Meeting – February 12, 2019

Outcome of the Board Meeting – February 12, 2019

Observation Letter – BSE

Observation Letter – NSE

Stock Exchange Letter Sun Pharma Investor Update

Stock Exchange Letter to SEBI on alleged second whistleblower complaint filed against Sun

Stock Exchange Letter update on commercialsed XELPROS in US

Stock Exchange Letter Completion of transaction Pola Pharma, Japan

Stock Exchange Letter Clarification on Recent Media Reports

Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Stock Exchange Letter Intimation of settlement in re Modafinil Antitrust Litigation in US with certain plaintiffs

Notice of Board meeting – Nov 13, 2018

Outcome of Board meeting – Nov 13, 2018

Intimation regarding inter-se change in shareholding of promoter group pursuant to Scheme of Amalgamation.

Complaint Report filed by the Company to National Stock Exchange of India Limited pursuant to filing of Draft Scheme of Arrangement

Complaint Report filed by the Company to BSE Limited pursuant to filing of Draft Scheme of Arrangement

Shareholding Pattern – September 30, 2018

Investor – Shareholder Information – Statutory Communications – 2018

Voting Results of 26th Annual General Meeting to Stock Exchanges along with Scrutinizers Report

Composite Scheme of Arrangement

Chairman speech at 26th Annual General Meeting held on September 26, 2018

Proceedings of 26th Annual General Meeting

Clarification to Stock Exchanges on Mohali facility

Clarification to Stock Exchanges on news regarding Halol facility

Newspaper Advertisement – Notice of 26th AGM, E-voting and Book Closure – English and Gujarati

Business Responsibility Report FY2017-18

Form for waiver-forgoing right to receive Dividend for financial year ended March 31, 2018

EMPLOYEES’ STOCK OPTION SCHEMES – Disclosure under SEBI (Share Based Employee Benefits) Regulations, 2014 as on March 31, 2018

Notice of 26th Annual General Meeting

Intimation of Book closure and AGM date

Outcome of Board Meeting – August 14, 2018

Notice of Board Meeting – August 14, 2018

Clarification on news regarding Halol

Voting Results of NCLT Meeting of Equity Shareholders

Proceedings of National Company Law Tribunal Meetings held on June 01, 2018

Outcome of Board Meeting May 25, 2018

Notice of Board Meeting – May 25, 2018

Allotment of Equity Shares under SUN ESOS 2015 – May 24, 2018

Newspaper Advertisement regarding Notice for NCLT Convened Meeting of Equity Shareholders & Unsecured Creditors and Notice for Remote E-Voting for NCLT Convened Meeting of Equity Shareholders

Shareholding Pattern

SPIL – Attendance Slip for NCLT Convened Meeting of Unsecured Creditors

SPIL – NCLT Convened Meeting Notices of Unsecured Creditors along with Proxy Form and Attendance Slip

SPIL – Attendance Slip for NCLT Convened Meeting of Equity Shareholders

SPIL – NCLT Convened Meeting Notices of Equity shareholders along with Proxy Form

Intimation to stock exchanges Mar 10 2018

Update on USFDA Halol Inspection

Disclosure to Stock Exchanges under Regulation 30 – Updates

Outcome of Board Meeting – February 14, 2018

Allotment of Equity Shares under SUN ESOS 2015 – February 14, 2018

SPIL Reply to BSE on News Clarification Ankleshwar unit Feb 5 2018

SPIL Reply to NSE on News Clarification Ankleshwar unit Feb 5, 2018

Notice of Board Meeting – February 14, 2018

Disclosure to Stock Exchanges under Regulation 30 – Updates

Scheme of Arrangement – Compliance of Regulation 37 of SEBI Listing Obligations and Disclosure Requirements Regulations 2015

Disclosure to Stock Exchanges under Regulation 30

Outcome of Board Meeting 14 November 2017

Outcome of Allotment Committee Meeting 14 November 2017

Notice of Board Meeting – November 14 2017

Outcome of Allottment Commitee Meeting September 26 2017

Update on US FDA Dadra Inspection

Voting Results for the 25th AGM and Scrutinizers Report

Chairman and Managing Director Speech at 25th Annual General Meeting held on September 26, 2017

Proceedings of 25th Annual General Meeting

Newspaper Advertisement Notice of AGM Evoting and Book Closure English Ahmedabad Edition

Newspaper Advertisement Notice of AGM Evoting and Book Closure English Mumbai Edition

Newspaper Advertisement Notice of AGM Evoting and Book Closure Gujarati Ahmedabad Edition

Form for waiver-forgoing of right to receive Dividend for the financial year ended March 31 2017

Business Responsibility Report 2016-17

ESOS – Disclosure under SEBI (Share Based Employee Benefits) Regulations, 2014 as on March 31, 2017

SPIL Notice of 25th AGM 2016-17

SPIL Attendance Slip and Proxy Form 2016-17

Outcome of Allottment Commitee Meeting August 11, 2017

Outcome of Board Meeting August 11, 2017

Notice of Board Meeting August 11 2017

Intimation of change in key managerial person for determining materiality of an event or information

Proceedings of NCLT Convened Meetings held on June 20, 2017

Scrutinizer’s Report for the NCLT Convened Meeting of Unsecured Creditors

Consolidated Scrutinizer’s Report for the NCLT Convened Meeting of Equity Shareholders

Voting Results of NCLT Convened Meeting of Equity Shareholders

Correction Letter to the Letter to Stock Exchange for outcome of Board Meeting May 26 2017

Outcome of Board Meeting May 26, 2017

Outcome of Allottment Commitee Meeting May 26, 2017

Newspaper Advertisement regarding Notice for Postal Ballot and Remote E-voting for the National Company Law Tribunal Convened Meeting of Equity Shareholders

Newspaper Advertisement regarding Notice of the National Company Law Tribunal Convened Meetings of Equity Shareholders and Unsecured Creditors

Notice of Board Meeting May 26, 2017

Notice of NCLT Convened Meeting of Equity Shareholders including Proxy Form and Attendance Slip

Notice of Tribunal Convened Meeting of Unsecured Creditors of the Company

Postal Ballot Form for NCLT Convened Meeting of Equity Shareholders

Acquisition of Thallion Pharmaceuticals Inc.

Observation letter – BSE

Observation letter – NSE

Outcome of Board Meeting February 14, 2017

Allottment Commitee Meeting Outcome of Meeting February 14, 2017

Notice of Board Meeting – February 14, 2017

Complaint Report filed by the Company to National Stock Exchange of India Limited pursuant to filing of Draft Scheme of Arrangement for Amalgamation

Complaint Report filed by the Company to BSE Limited pursuant to filing of Draft Scheme of Arrangement for Amalgamation

SPIL Reply to BSE on news clarification Ahmednagar unit Dec 29, 2016

SPIL Reply to NSE on news clarification Ahmednagar unit Dec 29, 2016

Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Scheme of Arrangement – Compliance of Regulation 37 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015

Update on acquisition of Ocular Technologies, Sarl – closure of transaction

Stock Exchange Letter – Reply

Stock Exchange Letter – Update on USFDA Inspection for Halol facility

Sun Pharma to acquire Biosintez in Russia

Allottment Commitee Meeting Outcome of Meeting

Stock Exchange Intimation on CFO

Notice of Board Meeting – 10th November, 2016

Change in Window Closure Date for trading by Designated Persons

Completion of Buyback and Submission of Post Buyback Public Announcement

Submission of Corrigendum to the Post Buyback Public Announcement

Receipt of approval for reclassification of shares under Regulation 31A(7) of the SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015

Submission of new set of Articles of Association of the Company

September 22, 2016

Voting Results of 24th Annual General Meeting held on September 17, 2016

September 19, 2016

Proceedings of 24th Annual General Meeting held on September 17, 2016

September 19, 2016

Srcutinizer’s Report on Voting Results of 24th Annual General Meeting held on September 17, 2016

September 19, 2016

Chairman and Managing Director Speech at 24th Annual General Meeting held on September 17, 2016

September 19, 2016

Letter of offer for Buyback

September 14, 2016

Draft Articles of Association of SPIL

August 27, 2016

Form for waiver forgoing right to receive Dividend for year ended 31-03-16

August 18, 2016

NOTICE OF 24th ANNUAL GENERAL MEETING

August 17, 2016

Business Responsibility Report 2015-16

August 17, 2016

Notice of Board meeting scheduled on August 12, 2016

August 05, 2016

Draft letter of offer for Buyback – Sun Pharmaceutical Industries Limited

July 08, 2016

Public Announcement of Sun Pharmaceutical Industries Limited for buyback through Tender Offer

June 28, 2016

Outcome of Board Meeting dated June 23, 2016

June 23, 2016

Outcome of the Board meeting held on 30th May, 2016

May 30, 2016

Intimation pertaining to Request letter(s) received from certain Promoter group under Regulation 31A of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

May 23, 2016

Notice of Board meeting scheduled on 30th May, 2016

May 13, 2016

Intimation of withdrawal of CARE rating at Company’s request

April 07, 2016

Termination of collaboration established in 2011 between affiliates of Merck Sharp & Dohme and Sun Pharmaceutical Industries Limited

February 15, 2016

Outcome of the Board meeting held on 12th February, 2016

February 12, 2016

Notice of Board Meeting scheduled on 12th February 2016

January 29, 2016

CCI approval for sale of CNS division to Strides

January 22, 2016

Disclosure to Stock Exchanges under Regulation 30

Top